following a full submission:
clostridium botulinum neurotoxin type A (Xeomin®) is accepted for use within NHSScotland.
Indication under review: for the symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults.
Clostridium botulinum neurotoxin type A improved unstimulated saliva flow rate and the Global Impression of Change Scale compared with placebo.
- Medicine name:
- clostridium botulinum neurotoxin type A (Xeomin)
- SMC ID:
Adult patients with chronic sialorrhoea due to neurological conditions.
- Pharmaceutical company
- Merz Pharma UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published:
- 11 November 2019